Cowen Starts Versartis (VSAR) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Citi Starts Versartis (VSAR) at Buy
April 15, 2014 7:05 AM EDTCiti initiated coverage on Versartis (NASDAQ: VSAR) with a Buy rating and a price target of $60.00.
For an analyst ratings summary and ratings history on Versartis click here. For more ratings news on Versartis click here.
Shares of Versartis closed at $24.56 yesterday.
... MoreMorgan Stanley Starts Versartis (VSAR) at Overweight
April 15, 2014 7:04 AM EDTMorgan Stanley initiated coverage on Versartis (NASDAQ: VSAR) with an Overweight rating and a price target of $79.00.
For an analyst ratings summary and ratings history on Versartis click here. For more ratings news on Versartis click here.
Shares of Versartis closed at $24.56 yesterday.
... MoreUPDATE: Canaccord Genuity Starts Versartis (VSAR) at Buy
April 15, 2014 7:03 AM EDT(Updated - April 15, 2014 11:38 AM EDT)
Canaccord Genuity initiated coverage on Versartis (NASDAQ: VSAR) with a Buy rating and a price target of $36.00.
"We believe Versartis product treating growth hormone deficiency is differentiated molecularly and provides significant advantages over current treatment including... More
